<DOC>
	<DOCNO>NCT02425670</DOCNO>
	<brief_summary>The purpose study determine whether patient subacute ischemic stroke benefit infusion patient 's bone marrow derive stem cell . Primary Hypothesis : Intravenous injection bone marrow mononuclear cell dose 30 500 million patient subacute ischemic stroke result reduction infarct volume improvement neurological function compare without injection . Secondary Hypothesis : Patients receive 100 million Bone marrow derive stem cell ( BMSC ) well outcome receive few dosage cell .</brief_summary>
	<brief_title>Stem Cell Therapy For Acute Ischemic Stroke Patients</brief_title>
	<detailed_description>Background : Stroke account significant disability need novel treatment modality improve functional outcome . In randomized clinical trial , investigator propose examine stem cell therapy potential therapeutic modality . Stem cell animal stroke model show reduction infarct size improvement neurological function . Only one human clinical trial intravenous autologous marrow stromal cell therapy five patient show benefit . The primary objective phase II study explore favourable risk benefit ratio autologous bone marrow derive mononuclear stem cell therapy ( BMSCs ) patient acute ischemic stroke justify large phase III trial . Methods &amp; Design : The study recruit 120 men woman age 18-70 year present acute ischemic stroke ( 7-29 day ) NIHSS score ≥ 7 BI ≤ 50 . Following baseline assessment ( MRI Brain , Whole Body PET scan , EEG brain , CT scan Brain clinical examination include National Institute Health Stroke Scale ( NIHSS ) , Barthel Index ( BI ) , modify Rankin Scale ( mRS ) , Glasgow Come Scale ( GCS ) , participant randomly allocate two group : conventional management alone ( control group ) ; conventional management autologous intravenous BMSCs transplantation ( experimental group ) . Bone marrow aspirate local anaesthesia isolate BMSCs cell inject intravenously within 4 hour . The patient monitor hemogram &amp; renal/liver function test , CT scan brain 36 hrs clinical examination week . The patient follow one year periodic MRI brain 3 month , 6 month , EEG &amp; PET scan 6 month 1 year . The primary efficacy outcome difference two group Modified Barthel index score modified Rankin Scale score six-month post-randomisation . The secondary efficacy outcome : NIHSS score six-months 1 year post-randomisation ; modify Rankin scale score 3 month one year post-randomization , functional status measure barthel index ( binary scale &lt; 60 &gt; 60 ) six month one year post-randomization . Dose response analysis do compare outcome patient receive various dos bone marrow mononuclear cell . Discussion : This phase 2 study aim explore favourable risk-to-benefit ratio stem cell therapy patient acute ischemic stroke . Investigators also plan examine whether justification phase III trial autologous bone marrow derive mononuclear stem cell therapy acute ischemic stroke .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Infarction , Middle Cerebral Artery</mesh_term>
	<mesh_term>Infarction , Anterior Cerebral Artery</mesh_term>
	<criteria>Patients judge eligible following : 1 . Sudden onset focal neurologic deficit impairment consciousness , 2 . Computerized tomographic MRI scan head show primary haematoma , relevant lesion within Middle Cerebral Artery ( MCA ) anterior cerebral artery ( ACA ) territory . Hemorrhagic change infarct acceptable . 3 . Age 18 75 year 4 . Seven day less 30 day since onset qualify event , 5 . Glasgow Coma Scale score 8 time randomization , aphasic Eye Motor score 6 , 6 . Modified Barthel index score 50 less time randomization . 7 . NIHSS score 7 point inability walk unaided raise upper limb 90 ° 8 . Patient stable : A patient define stable normal respiration , afebrile , BP le mean arterial pressure 125mm Hg ( hypotension define systolic BP &lt; 90mmHg ) , fast venous blood sugar level le 200mg % normal urea/electrolytes least 48 hour . Patients meet inclusion criterion consider ineligible study one following : 1 . Lacunar syndrome 2 . Intubation 3 . Posterior Circulation Stroke 4 . Comorbidity likely limit survival less three year e.g . malignant disease , hepatic renal failure 5 . Prestroke disability lead dependence others activity daily live , 6 . Inaccessibility followup 7 . Allergy local anaesthetic 8 . Unwillingness provide write informed consent self assent next kin . 9 . Symptom Acute myocardial infarction acute involvement organ . 10 . Pregnancy 11 . Human immunodeficiency virus ( HIV ) /hepatitis C virus ( HCV ) /HbsAg positive . 12 . Patient part trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Brain attack</keyword>
	<keyword>stroke</keyword>
	<keyword>Ischemic stroke</keyword>
	<keyword>stem cell therapy</keyword>
</DOC>